OhioHealth Riverside Methodist Hospital
Columbus, OH
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Accepting patients
LINKER-MM5
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (LINKER-MM5)
- Bispecific Antibody
- T Cell Engager (TCE)
- BCMA
- Phase 3
Accepting patients
Belantamab Mafodotin Combination Therapy
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1/2
Accepting patients
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
Not yet accepting
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- BCMA
- Phase 3
Not currently accepting
Early Detection Blood Tests
Blinded Reference Set for Multicancer Early Detection Blood Tests
- Observational Trial